Open AccessHymenialdisine is Cytotoxic Against Cisplatin-Sensitive but not Against Cisplatin-Resistant Cell Lines
Author(s) -
Nada Abdullah,
Najwa Al Balushi,
Syed Imran Hassan,
Shadia Al Bahlani,
Sergey Dobretsov,
Yahya Tamimi,
Ikram Burney
Publication year - 2021
Publication title -
sultan qaboos university medical journal
Language(s) - English
Resource type - Journals
eISSN - 2075-0528
pISSN - 2075-051X
DOI - 10.18295/squmj.4.2021.049
Subject(s) - cisplatin , cytotoxic t cell , medicine , ovarian cancer , cell culture , ic50 , cancer research , cytotoxicity , cancer , chemotherapy , oncology , pharmacology , in vitro , biology , biochemistry , genetics
Objectives: New compounds are needed to overcome the resistance to commonly used cytotoxic chemotherapy for epithelial ovarian cancer. Marine sponges are a rich source of diverse chemical compounds and hymenialdisine has been found to have antiproliferative effects. This study aimed to investigate the cytotoxic effect of hymenialdisine in cisplatin-sensitive and cisplatin resistant ovarian cancer cell lines. Methods: This study took place at Sultan Qaboos University, Muscat, Oman between August and November, 2019. The anti-cancer effects of hymenialdisine or cisplatin were assessed using treating cells with different concentrations of hymenialdisine and cisplatin. Cell viability was determined using the AlamarBlue® Assay. Results: The half-maximal inhibitory concentration (IC50) of cisplatin was estimated at 31.4 μM for A2780S and 76.9 μM for A2780CP, whereas the IC50 of hymenialdisine was evaluated at 146.8 μM for A2780S cells. Despite the higher concentrations of hymenialdisine (up to 300 μM), IC50 could not be determined for the A2780CP cell line. Conclusion: When compared to cisplatin, hymenialdisine was less toxic against both A2780S and A2780CP ovarian cancer cell lines.Keywords: Gynecologic Neoplasm; Ovarian Cancer; Cisplatin; Hymenialdisine; Oman.